OpenWav Launches AI-Powered Music Platform, Empowering Artists to Earn, Engage, and Build Fan-Driven Movements
LOS ANGELES--(BUSINESS WIRE)-- OpenWav today launched a revolutionary new music platform where artists engage with fans and deliver exclusive merchandise, ticketing, and digital content experiences — all while valuing creativity and building sustainable careers.
OpenWav redefines the future of independent music through its all-in-one, AI-powered model for monetization, fan engagement, and creative ownership.
As part of its official debut, OpenWav is launching during A2IM Indie Week in New York City, one of the most influential gatherings for the independent music community. To celebrate, the company is hosting a special Happy Hour on Wednesday, June 11, featuring Grammy-winning artist and OpenWav Chief Creative Officer Wyclef Jean, OpenWav Co-Founder Jaeson Ma, and music executive Madeline Nelson. The event will introduce the platform to industry leaders, showcasing how OpenWav redefines the future of independent music through its all-in-one, AI-powered model for monetization, fan engagement, and creative ownership.
Jaeson Ma, CEO and Co-Founder of OpenWav, said, 'The music industry is broken. Most artists can't make a living off streams, and social media rewards clout, not connection. OpenWav was built to change that. We're giving artists the power to monetize their superfans directly, own their audience, and finally build a real, sustainable career doing what they love. No middlemen. No gatekeepers. Just artists in full control.'
OpenWav's new economic model empowers independent and rising artists to generate meaningful revenue in the face of the current broken model of streaming, social media, and ticketing that commoditizes music and creativity, while generating unlivable payouts. The platform's AI-powered tools additionally provide valuable insights and analytics, enabling artists to understand their audience better and tailor their content strategy. In early testing, artists generated five figures per week on OpenWav, exceeding what the vast majority of artists earn in a year from streaming.
OpenWav integrates music streaming with social commerce, ticketing, and fan communities, allowing artists to build multifaceted campaigns around new music releases and existing catalogues. With OpenDesign's robust tools, artists can design premium products with AI, price and launch exclusive merchandise that ships worldwide — with no upfront costs.
Wyclef Jean said, 'Coming into this game as a young composer, having a chance to produce for The Fugees, Destiny's Child, and Shakira, just to name a few, my passion has always been about discovering. I really believe deep in my soul that with OpenWav, we are headed back in that direction. The system is currently constructed in a way that prioritizes promotion and algorithms over artistry. But OpenWav does the reverse, putting artists first. This is why I'm energized about what OpenWav is building right now. They're creating a pathway for artists to get discovered, build a solid foundation, and create a sustainable business model for themselves rooted in cultural currency that is true to them. The platform allows them to bypass the gatekeepers, creating a platform built on artistic equity — from events to merch. The future of music we all want to see is right here.'
Eric Tu, OpenWav Co-Founder and CTO, said, 'We're not just launching a platform, we're launching a movement to redefine the future of independent music and give rising stars a chance to build superfandom right from the very beginning. We built OpenWav to empower indie artists with tools to gain control of their artistry and superfans.'
From day one of downloading OpenWav, artists are provided detailed instructions and videos about how to monetize their work using the in-app creator tools and engage with their fans. Later this summer, OpenWav will announce an industry-disrupting discovery competition, offering rising artists the opportunity to share their original songs and receive valuable feedback from leading music industry professionals. Judges will evaluate submissions based on creativity, originality, and overall musical composition. For more information and future updates, follow @openwav_official on social media channels.
OpenWav is co-led by media executive, artist, and serial entrepreneur Jaeson Ma, who has a successful track record launching companies including EST Studios, Stampede Ventures, East West Ventures, and 88rising, and who's raised capital and advised on transactions totaling over $1 billion; and Eric Tu, an award-winning development executive who's worked with major brands including Nike, Beats by Dre and Google. Notable investors include Connect Ventures – a creator economy-focused fund backed by CAA / NEA, Warner Music Group, Goodwater Capital, Soma Capital, SuperScrypt, Dragonfly, Galaxy Interactive, and Animoca Brands.
About Wyclef Jean
Wyclef Jean, a three-time Grammy-winning producer, actor, and philanthropist, has been a prominent figure in music for over two decades, both as a solo artist with seven albums selling nearly nine million copies and as the founder of the Fugees. The Haitian-born singer-songwriter, who plays multiple instruments, started with The Refugee Camp before launching his solo career in 1997 with "Wyclef Jean Presents the Carnival Featuring the Refugee All-Stars." His subsequent albums explored diverse musical styles and his Haitian heritage. Over the last decade, Jean has also contributed to film and collaborated with numerous rap and R&B artists.
About Madeline Nelson
Madeline Nelson is an Emmy-nominated producer, Grammy Award-winning artist manager, influential music executive, and women's rights advocate with over three decades of experience shaping the world of music and culture. She is the founder and CEO of the newly formed Purple Cow Innovation, a boutique entertainment agency staffed completely by women, and co-founder of SodoMoodLab, a music jingle/ scoring company. Previously, Madeline has held numerous roles across music and culture spaces, including Head of Independent Label Relations for Amazon Music's Indie Division, SVP at Sony Music Entertainment, and SVP at Donna Karan's Urban Zen Foundation. Madeline Nelson's unique strength lies in her blend of sharp business sense and artistic intuition, driving innovative work across diverse creative fields. She prioritizes integrity and equity, particularly for women, and her mentorship has propelled many into successful careers, solidifying her impact on the industry.
About OpenWav
OpenWav is a next generation music platform that empowers artists to monetize and engage their superfan communities, available on the App Store and Google Play Store. OpenWav enables artists to create their own branded products risk-free, while providing world-class proprietary technology tools and global supply chain.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Financing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close SOUTH SAN FRANCISCO, Calif., June 12, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Sabrina Carpenter Poses Naked and Rocks Rapunzel Hair on Shocking NSFW 'Rolling Stone' Cover
Sabrina Carpenter bared all — literally — for her new Rolling Stone magazine cover The pop star, who opened up about her new album Man's Best Friend, wore next to nothing for the shoot In an October 2024 interview with Elle, the singer responded to comments about her lingerie-forward wardrobeSabrina Carpenter is giving everyone a show. The "Espresso" singer, 26, stripped down for Rolling Stone's Summer Issue, and the look is so jaw-droppingly sexy that it tops her past skin-baring moments. Published on June 12, the cover shows the Grammy winner kneeling while nude — save for lace-trimmed thigh-high socks and her hair, which is giving some serious mane character energy. For the shoot, Carpenter's '60s soda-can curls were transformed into Rapunzel-level tresses that strategically covered her nude figure. She sported her signature glam with big, feathery eyelashes and rosy cheeks. Accompanying Carpenter's Rolling Stone cover story, in which she opens up about making Man's Best Friend (her new album comes out on Aug. 29), are images of the former Disney Channel star clad in lacy lingerie looks. One of shots sees her posing in a floral lace-up corset and wood stilettos while another has her looking like well, a rated-R Disney princess in a blue gingham dress, unbuttoned to show off her matching briefs and bra. Not too long ago, Carpenter kicked off her new era with her single "Man Child," which she teased with a NSFW trailer that saw her hitchhiking in denim booty shorts. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Provocative looks have become synonymous with Carpenter's brand, especially since she embarked on her Short n' Sweet chapter last summer. And while the pop star has become one of fashion's most recognizable stars, her style has been hit with criticism for being too sexual. Though, she hasn't so much as bat an eyelid to the scrutiny. In an October 2024 interview with Elle, she said that doesn't let the critics get to her because she simply doesn't pay attention to it. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! 'Someone told me this, whenever I would get upset or feel like I'm the only one getting criticized for something other people are able to do seemingly so freely: I'm the one that's seeing all the negative shit about myself. My friends don't see that.' Yet, when she saw criticism on her 2025 Met Gala look on social media this past May, she wasn't so shy about clapping back. "Damn I f----- up," she said in response to an X user lamenting about her pantless Louis Vuitton look. Read the original article on People
Business Wire
41 minutes ago
- Business Wire
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ('Quince' or the 'Company'), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ('Warrants') that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (N eurological E ffects of e DSP on Subjects with A - T; NCT06193200 / IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law.
